Home›Trial›NCT07223216
NCT07223216Phase 1ACTIVE NOT RECRUITING

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Study Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.

Conditions
Obesity
Interventions / Drugs
BMF-650
View on ClinicalTrials.gov ↗
Sponsor
BMEA
Biomea Fusion
Covalent Small Molecules
D44/100
Study Details
Enrollment80 participants
Primary Completion—
Lead SponsorBiomea Fusion Inc.
Data Retrieved2026-04-11 04:08:06.413434+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 80 participants
Sponsor Catalyst Profile

Biomea Fusion (BMEA) is the sponsoring company for this trial. BiotechSign currently grades this company D (44/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BMEA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.